{"nctId":"NCT04296890","briefTitle":"A Study of Mirvetuximab Soravtansine in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression","startDateStruct":{"date":"2020-07-23","type":"ACTUAL"},"conditions":["Epithelial Ovarian Cancer","Peritoneal Cancer","Fallopian Tube Cancer"],"count":106,"armGroups":[{"label":"Treatment","type":"EXPERIMENTAL","interventionNames":["Drug: Mirvetuximab Soravtansine"]}],"interventions":[{"name":"Mirvetuximab Soravtansine","otherNames":["IMGN853","MIRV"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Female participants ≥ 18 years of age\n2. Participants must have a confirmed diagnosis of high-grade serous epithelial ovarian cancer (EOC), primary peritoneal cancer, or fallopian tube cancer\n3. Participants must have platinum-resistant disease:\n\n   1. Participants who have only had 1 line of platinum based therapy must have received at least 4 cycles of platinum, must have had a response (complete response/remission \\[CR\\] or partial response/remission \\[PR\\]) and then progressed between \\> 3 months and ≤ 6 months after the date of the last dose of platinum\n   2. Participants who have received 2 or 3 lines of platinum therapy must have progressed on or within 6 months after the date of the last dose of platinum\n\n   Note: Progression should be calculated from the date of the last administered dose of platinum therapy to the date of the radiographic imaging showing progression\n\n   Note: Participants who are platinum refractory during front-line treatment are excluded (see exclusion criteria)\n4. Participants must have progressed radiographically on or after their most recent line of anticancer therapy.\n5. Participants must be willing to provide an archival tumor tissue block or slides, or undergo procedure to obtain a new biopsy using a low-risk, medically routine procedure for immunohistochemistry (IHC) confirmation of Folate Receptor α (FRα) positivity\n6. Participant's tumor must be positive for FRα expression as defined by the Ventana FOLR1 Assay\n7. Participants must have at least 1 lesion that meets the definition of measurable disease by RECIST v1.1 (radiologically measured by the Investigator)\n8. Participants must have received at least 1 but no more than 3 prior systemic lines of anticancer therapy, including at least 1 line of therapy containing bevacizumab, and for whom single-agent therapy is appropriate as the next line of treatment:\n\n   1. Adjuvant ± neoadjuvant considered 1 line of therapy\n   2. Maintenance therapy (e.g., bevacizumab, poly adenosine diphosphate-ribose polymerase (PARP) inhibitors) will be considered part of the preceding line of therapy (i.e., not counted independently)\n   3. Therapy changed due to toxicity in the absence of progression will be considered part of the same line (i.e., not counted independently)\n   4. Hormonal therapy will be counted as a separate line of therapy unless it was given as maintenance\n9. Participants must have an Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 or 1\n10. Participants must have completed prior therapy within the specified times below:\n\n    1. Systemic antineoplastic therapy within 5 half-lives or 4 weeks (whichever is shorter) prior to first dose of MIRV\n    2. Focal radiation completed at least 2 weeks prior to first dose of MIRV\n11. Participants must have stabilized or recovered (Grade 1 or baseline) from all prior therapy-related toxicities (except alopecia)\n12. Participants must have completed any major surgery at least 4 weeks prior to first dose of MIRV and have recovered or stabilized from the side effects of prior surgery\n13. Participants must have adequate hematologic, liver and kidney functions defined as:\n\n    1. Absolute neutrophil count (ANC) ≥ 1.5 x 10\\^9/L (1,500/μL) without G-CSF in the prior 10 days or long-acting WBC growth factors in the prior 20 days\n    2. Platelet count ≥ 100 x 10\\^9/L (100,000/μL) without platelet transfusion in the prior 10 days\n    3. Hemoglobin ≥ 9.0 g/dL without packed red blood cell (PRBC) transfusion in the prior 21 days\n    4. Serum creatinine ≤ 1.5 x upper limit of normal (ULN)\n    5. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 3.0 x ULN\n    6. Serum bilirubin ≤ 1.5 x ULN (patients with documented diagnosis of Gilbert syndrome are eligible if total bilirubin \\< 3.0 x ULN)\n    7. Serum albumin ≥ 2 g/dL\n14. Participants or their legally authorized representative must be willing and able to sign the informed consent form (ICF) and to adhere to the protocol requirements\n15. Women of childbearing potential (WCBP) must agree to use highly effective contraceptive method(s) while on MIRV and for at least 3 months after the last dose\n16. WCBP must have a negative pregnancy test within the 4 days prior to the first dose of MIRV\n\nExclusion Criteria:\n\n1. Male participants\n2. Participants with endometrioid, clear cell, mucinous, or sarcomatous histology, mixed tumors containing any of the above histologies, or low-grade/borderline ovarian tumor\n3. Participants with primary platinum-refractory disease, defined as disease that did not respond to (CR or PR) or has progressed within 3 months of the last dose of first-line platinum-containing chemotherapy\n4. Participants with prior wide-field radiotherapy (RT) affecting at least 20 percent of the bone marrow\n5. Participants with \\> Grade 1 peripheral neuropathy per Common Terminology Criteria for Adverse Events (CTCAE)\n6. Participants with active or chronic corneal disorders, history of corneal transplantation, or active ocular conditions requiring ongoing treatment/monitoring, such as uncontrolled glaucoma, wet age-related macular degeneration requiring intravitreal injections, active diabetic retinopathy with macular edema, macular degeneration, presence of papilledema, and /or monocular vision\n7. Participants with serious concurrent illness or clinically relevant active infection, including, but not limited to the following:\n\n   1. Active hepatitis B or C infection (whether or not on active antiviral therapy)\n   2. Human immunodeficiency virus (HIV) infection\n   3. Active cytomegalovirus infection\n   4. Any other concurrent infectious disease requiring IV antibiotics within 2 weeks prior to the first dose of MIRV\n\n   Note: Testing at screening is not required for the above infections unless clinically indicated\n8. Participants with a history of multiple sclerosis (MS) or other demyelinating disease and/or Lambert-Eaton syndrome (paraneoplastic syndrome)\n9. Participants with clinically significant cardiac disease including, but not limited to, any of the following:\n\n   1. Myocardial infarction ≤ 6 months prior to first dose\n   2. Unstable angina pectoris\n   3. Uncontrolled congestive heart failure (New York Heart Association \\> class II)\n   4. Uncontrolled ≥ Grade 3 hypertension (per CTCAE)\n   5. Uncontrolled cardiac arrhythmias\n10. Participants with a history of hemorrhagic or ischemic stroke within 6 months prior to enrollment\n11. Participants with a history of cirrhotic liver disease (Child-Pugh Class B or C)\n12. Participants with a previous clinical diagnosis of noninfectious interstitial lung disease (ILD), including noninfectious pneumonitis\n13. Participants requiring use of folate-containing supplements (eg, folate deficiency)\n14. Participants with prior hypersensitivity to monoclonal antibodies (mAb)\n15. Women who are pregnant or breastfeeding\n16. Participants who received prior treatment with MIRV or other FRα-targeting agents\n17. Participants with untreated or symptomatic central nervous system (CNS) metastases\n18. Participants with a history of other malignancy within 3 years prior to enrollment.\n\n    Note: Participants with tumors with a negligible risk for metastasis or death (eg, adequately controlled basal-cell carcinoma or squamous-cell carcinoma of the skin, or carcinoma in situ of the cervix or breast) are eligible\n19. Prior known hypersensitivity reactions to study drugs and/or any of their excipients","healthyVolunteers":false,"sex":"FEMALE","genderBased":true,"minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Objective Response Rate (ORR): Percentage of Participants With Objective Response as Assessed by the Investigator Using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1)","description":"ORR was defined as percentage of participants with a confirmed best overall response (BOR) of complete response (CR) or partial response (PR). CR: Disappearance of all target or non-target lesions. All pathological or non-pathological lymph nodes (whether target or non-target) must have reduction in short axis to \\<10 millimeters (mm). PR: At least 30% decrease in the sum of the longest diameters (SoD) of target lesions, taking as reference the baseline SoD.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"32.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Duration of Response (DOR) as Assessed by the Investigator Using RECIST v1.1","description":"DOR was defined as the time from the date of the first response (CR or PR), until the date of progressive disease (PD) or death from any cause, whichever occurred first. DOR for participants who had not progressed or died at the time of analysis was censored at the date of their last tumor assessment. PD: At least a 20% increase in the SoD of target lesion, taken as reference the smallest (nadir) SoD since and including baseline. In addition to the relative increase of 20%, the SoD must also demonstrate an absolute increase of at least 5 mm. Unequivocal progression of non-target lesions. Unequivocal progression should not normally trump target lesion status. It must be representative of overall disease status change, not a single lesion increase. DOR was estimated using the Kaplan-Meier method.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.93","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With CA-125 Confirmed Clinical Response Per Gynecologic Cancer Intergroup (GCIG) Criteria","description":"The GCIG CA-125 response was defined as at least 50% reduction in CA-125 levels from baseline. The response must have been confirmed and maintained for at least 28 days.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"46.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Progression-Free Survival (PFS) as Assessed by the Investigator Using RECIST v1.1","description":"PFS was defined as the time from initiation of study drug until the date of PD or death whichever occurred first, estimated using the Kaplan-Meier method. PD: At least a 20% increase in the SoD of target lesion, taken as reference the smallest (nadir) SoD since and including baseline. In addition to the relative increase of 20%, the SoD must also demonstrate an absolute increase of at least 5 mm. Unequivocal progression of non-target lesions and appearance of new lesions. Unequivocal progression should not normally trump target lesion status. It must be representative of overall disease status change, not a single lesion increase.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.27","spread":null}]}]}]},{"type":"SECONDARY","title":"Overall Survival Assessed by the Investigator Using RECIST v1.1","description":"Overall survival was defined as the time from the date of first dose until the date of death from any cause, estimated using the Kaplan-Meier method.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"15.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Treatment-emergent Adverse Events (TEAEs)","description":"An adverse event (AE) was defined as any untoward medical occurrence that develops or worsens in severity during the conduct of a clinical study and does not necessarily have a causal relationship to study drug. TEAEs were defined as AEs with an onset date on or after the first dose of Study drug, and within 30 days of the last dose of study drug or prior to the start of a new anticancer treatment, whichever occurred first. A summary of all Serious Adverse Events (SAEs) and Other Adverse Events (nonserious) regardless of causality is located in the 'Reported Adverse Events' Section.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"105","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":36,"n":106},"commonTop":["Vision blurred","Nausea","Keratopathy","Diarrhoea","Fatigue"]}}}